Back

Use of Levosimendan in patients with INTERMACS 3 profile: weaning from inotropic support and short- to medium-term evolution

8 March 2024 (08:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Poster session 1 Cardiogenic Shock ACVC Premium Access ESC Acute CardioVascular Care 2024 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Miss Stefana Enachi

Cardiovascular Diseases Institute Prof. Dr. George I.M. Georgescu, Iasi (Romania)

45 More presentations in this session

Presentation thumbnail
Diagnostic and prognostic value of NT-proBNP in patients with non-alcoholic fatty liver disease and acute decompensated heart failure.
Doctor N. Khutsishvili (Tbilisi, GE)
Abstract
Presentation thumbnail
Intravenous angiotensin II as an add-on to standard of care vasopressors in patients with refractory shock on mechanical circulatory support: a single centre retrospective case series
Miss D. Sipus (Zagreb, HR)
Abstract
Presentation thumbnail
Reperfusion therapies in patients with intermediate- and high-risk pulmonary embolism: insights from a multicenter registry
Doctor C. Real (Madrid, ES)
Abstract
Presentation thumbnail
Predictive value of procalcitonin for early atrial fibrillation recurrence post-cardioversion at the emergency department
Doctor A. Diakantonis (Chaidari, GR)
Abstract
Presentation thumbnail
Influence of age on the incidence of acute complete atrioventricular block in right coronary artery infarction.
Doctor M. Lopez Flores (Seville, ES)
Abstract

Access the full session

Session thumbnail
Poster session 1

The Event

Event poster

ESC Acute CardioVascular Care 2024

8 March 2024 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Experience with levosimendan in cardiogenic shock: inotrope weaning and clinical outcomes in a real-world cohort
thumbnail
Congress Presentation
The effect of Levosimendan in weaning from veno-arterial extracorporeal membrane oxygenation in patients with postcardiotomy shock
thumbnail
Congress Presentation
Stabilizing the unstable: characterization of advanced heart failure patients under intermittent levosimendan therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources